CTOs on the Move

Aclario

www.aclairo.com

 
Aclario is a Vienna, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.aclairo.com
  • 1950 Old Gallows Rd Ste 300
    Vienna, VA USA 22182
  • Phone: 703.506.6760

Executives

Name Title Contact Details

Similar Companies

Journey Medical

Journey’s purpose is to positively impact people by providing effective solutions for treating skin conditions, healing wounds, and supporting healthy skin.

Apex Clinical

Apex Clinical is a Apex, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.

Almirall

With over 1,975 employees, it has a presence, through its 13 affiliates in Europe and United States.

Neurogastrx

We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.